FAQ/Help |
Calendar |
Search |
Today's Posts |
|
Parkinson's Disease Clinical Trials For posting and discussion of clinical trials related to Parkinson's Disease, and for the Parkinson Pipeline Project. All are welcome. |
Reply |
|
Thread Tools | Display Modes |
|
05-04-2011, 04:39 PM | #1 | ||
|
|||
Junior Member
|
Impax, the sponsor of the IPX066 trial just sent out the following message:
“Our internal work on the new open label extension study was put on hold while our Senior Management reviewed our projects, resources and budgets. Today we learned that we will not be moving forward with this study. We will, however, be working diligently to submit our NDA [Impax’s request for FDA approval of the study drug so it can be made available to the public] this year so that IPX066 will be available to patients once it is approved. We appreciate all of your efforts on our studies and know that this will be disappointing to your study staff and the patients.” This is really bad news for those of us who volunteered to take the risk of being in the IPX066 study and now are being sent back to drugs like sinemet, which have serious side effects. It seems to me that they have used us and, having gotten the data they need, now feel no obligation to us at all. |
||
Reply With Quote |
05-11-2011, 07:27 AM | #2 | ||
|
|||
In Remembrance
|
Many clinical trial participants feel that way after they find out it's canceled. i'm sorry for yet another disappointing story about a treatment not making it past phase 2. did they tell you why? did they provide any results?
Quote:
__________________
paula "Time is not neutral for those who have pd or for those who will get it." |
||
Reply With Quote |
05-11-2011, 03:05 PM | #3 | ||
|
|||
Junior Member
|
Paula, the IPX066 open label extension that was cancelled was a follow-on to several earlier successful trials. The company had promised that participants in those earlier trials would be able to continue to use the test drug (IPX066) until it was approved for sale. The company changed their mind and cancelled the extension, thereby forcing the trial participants back to inferior drugs like sinemet. They didn't say why they changed their mind, but I suspect it was due to the fear that they had little to gain from the extension and possibly a lot to lose if abnormalities showed up in the extension.
|
||
Reply With Quote |
"Thanks for this!" says: | paula_w (05-12-2011) |
05-12-2011, 01:18 PM | #4 | ||
|
|||
In Remembrance
|
Quote:
please don't just accept what they've done. It should be a crime.
__________________
paula "Time is not neutral for those who have pd or for those who will get it." |
||
Reply With Quote |
05-12-2011, 01:36 PM | #5 | ||
|
|||
In Remembrance
|
Do you have that commitment in writing to let the participants continue on it until approval?
__________________
paula "Time is not neutral for those who have pd or for those who will get it." |
||
Reply With Quote |
08-13-2011, 10:08 AM | #6 | ||
|
|||
New Member
|
Any updates?
|
||
Reply With Quote |
08-13-2011, 12:34 PM | #7 | ||
|
|||
Junior Member
|
I have had no success in getting the company to reconsider their decision to deny access to former trial participants. They are continuing to sponsor new trials of IPX066, but are not allowing previous trial participants to enroll.
I suggest you contact Impax Labs' president and the study director, Dr. Jeff Mulchahey. I can't post their email addresses (due to rules of this site). If you email me, I will try to help you contact them. |
||
Reply With Quote |
08-13-2011, 01:14 PM | #8 | ||
|
|||
New Member
|
Quote:
|
||
Reply With Quote |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
YALE - A Different SPECT Scan Study is Open | Parkinson's Disease | |||
Teriflunomide: results of an open-label 144-week extension study | Multiple Sclerosis |